688 related articles for article (PubMed ID: 30208475)
1. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
[TBL] [Abstract][Full Text] [Related]
2. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
[TBL] [Abstract][Full Text] [Related]
3. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age.
Wood N; McIntyre P; Marshall H; Roberton D
Pediatr Infect Dis J; 2010 Mar; 29(3):209-15. PubMed ID: 20009964
[TBL] [Abstract][Full Text] [Related]
4. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
6. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
7. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
[TBL] [Abstract][Full Text] [Related]
8. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
10. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
Pérez Chacón G; Estcourt MJ; Totterdell J; Marsh JA; Perrett KP; Campbell DE; Wood N; Gold M; Waddington CS; O' Sullivan M; McAlister S; Curtis N; Jones M; McIntyre PB; Holt PG; Richmond PC; Snelling T
PLoS Med; 2024 Jun; 21(6):e1004414. PubMed ID: 38857311
[TBL] [Abstract][Full Text] [Related]
12. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
13. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Wood N; Marshall H; White OJ; Holt PG; McIntyre P
Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
[TBL] [Abstract][Full Text] [Related]
14. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial.
Munoz FM; Bond NH; Maccato M; Pinell P; Hammill HA; Swamy GK; Walter EB; Jackson LA; Englund JA; Edwards MS; Healy CM; Petrie CR; Ferreira J; Goll JB; Baker CJ
JAMA; 2014 May; 311(17):1760-9. PubMed ID: 24794369
[TBL] [Abstract][Full Text] [Related]
17. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
[No Abstract] [Full Text] [Related]
18. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
[TBL] [Abstract][Full Text] [Related]
19. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
20. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Perrett KP; Halperin SA; Nolan T; Carmona Martínez A; Martinón-Torres F; García-Sicilia J; Virta M; Vanderkooi OG; Zuccotti GV; Manzoni P; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Stranak Z; Merino Arribas JM; Cilleruelo Ortega MJ; Miranda-Valdivieso M; Arias Novas B; Ramos Amador JT; Omeñaca F; Baca M; Marchisio PG; Mesaros N
Vaccine; 2020 Feb; 38(8):2105-2114. PubMed ID: 31776027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
